SNY (Sanofi S.A.) Future Price to Earnings

Brandmark of Sanofi (SNY)

Under the leadership of Paul Hudson, Sanofi is focusing on immunology and vaccines while reducing its mass-market exposure. Opening the company's forward P/E ratio on GURU.Markets, we observe that the 9.20 metric determines this level. Stable demand for drugs protects the asset, although Asian supply chain disruptions and patent disputes create geopolitical risks.

Future Price to Earnings: sanofi.com (SNY) for 07/04/2022 - 11/14/2026

Analytical breakdowns and data insights for company sanofi.com (SNY)

- stock quotes and analyst forecast:
Stock Price Sanofi Aventis|SNY - Fair Value Consensus
- business market valuation indicators:
Market Value Sanofi SA|SNY - Total Enterprise Value
- balance sheet equity data:
Net Assets per Single Share Sanofi|SNY - Company Book Value|Market Capitalization to Book Value Ratio sanofi.com|SNY - Total Business Assets
- debt level and financial liquidity data:
Total Debt to Capital Sanofi|SNY - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Sanofi Aventis|SNY - Company Aggregate Debt|Debts to Book Capitalization Sanofi Group|SNY - Long-Term Indebtedness|Company Short-Term Debt Sanofi|Quick Ratio sanofi.com
- company profitability and valuation multiples indicators:
SNY - Net Profit|Expected Profit Sanofi|SNY - Price to Earnings Multiple|Future Price to Earnings Sanofi SA|SNY - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple Sanofi Aventis|SNY - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Sanofi|SNY - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months sanofi.com|SNY - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Sanofi
- issuer revenue and sales details:
SNY - Company Sales Volume|Company Future Sales Volume sanofi.com|SNY - Price to Sales|Price-to-Projected Revenue Ratio Sanofi Aventis
Summary company analytics:Sanofi SA
Brand item of Sanofi

The operational efficiency of Sanofi (SNY) directly determines the market expectations captured by this indicator. The company's expected price-to-earnings ratio compares current market capitalization with projected earnings, revealing the degree of market optimism regarding future margins. An increasing ratio signals confidence in the growth strategy. The implementation of ESG standards and non-commercial drug supplies create long-term value, mitigating operational cost risks. The stability of this metric confirms the fundamental resilience of the business.

Competitor analysis

Forward P/E Multiple LLY|ABBV (Abbvie) - Future Price to Earnings Multiple|Future Price to Earnings AstraZeneca Plc AZN|novartis.com (NVS) - Projected Price to Earnings Ratio|MRK - Future Price to Earnings|NVO: Future Price to Earnings|Amgen Corporation (AMGN) - Future Price to Earnings|Price to Future Earnings Ratio PFE|BMY (bms.com) - Forward P/E Multiple|gsk.com (GSK) - Market Cap to Projected Earnings|Future Price to Earnings Takeda Pharmaceutical Company Limited (TAK)|Market Cap to Projected Earnings Teva Pharma|Forward P/E Multiple RDY (Dr. Reddy's Laboratories Limited)|VTRS: Price to Future Earnings Ratio|Roivant Corp - Forward P/E Multiple|Forward Price to Earnings Multiple Zai Lab (ZLAB)|BHC: Forward P/E Multiple|Projected Price to Earnings Cosmos Health, Inc.